Radiat Oncol J.  2022 Sep;40(3):192-199. 10.3857/roj.2022.00101.

Bone-only oligometastatic prostate cancer: can SABR improve outcomes? A single-center experience

• Sánchez-Iglesias ÁL
• Morillo-Macías V
• Santafé-Jiménez A
• Ferrer-Albiach C

• KMID: 2533419
• DOI: http://doi.org/10.3857/roj.2022.00101

Abstract

Purpose
Ablative treatment of oligometastases has shown survival benefit with certain tumors, although these effects still are to be demonstrated in prostate cancer.
Materials and Methods
We analysed the toxicity and clinical control results obtained in patients with bone-only oligometastatic prostate cancer treated with stereotactic ablative radiotherapy (SABR). Retrospective study on patients with metachronous oligoprogression and synchronous de novo bone-only oligometastatic prostate cancer treated with SABR and androgen deprivation therapy.
Results
Treatment schedules varied according to location and organs at risk, with biologically equivalent dose (BED) ≥100 Gy. Fifty-five bone lesions (31 patients) were treated and evaluated for toxicity, local control, progression-free survival (PFS), and overall survival (OS). After a 41-month follow-up, there was minimal acute or chronic toxicity and no G3 toxicity. The local control at 3 and 5 years was 100% and 87.1%, respectively. Median PFS and OS were 43 and 98 months, respectively. The best result in PFS was obtained with BED ≥230 Gy, delaying time to the next systemic therapy by 28.5 months.
Conclusion
The use of SABR in bone oligometastases of prostate cancer is safe with minimal toxicity and excellent results in local control and PFS, delaying the start of the next systemic therapy.

Keyword

SABR; Stereotactic ablative radiotherapy; Bone oligometastases; Prostate cancer; NEST; Next systemic therapy